Abstract: Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics. The disclosure in some aspects also relates to methods for identifying subjects for treatment of fibromyalgia with administration of psychedelics. In some aspects, the treatment also involves psychotherapy. In some aspects, the subject receiving the treatment is assessed for various indicators, such as observer-rated and subject-reported outcomes, biological and clinical indicators, and combinations thereof.

Abstract: Provided are improved methods for treating a psychological disorder in a subject comprising administering to the subject an amount of psilocybin or psilocin sufficient to induce a dissociative state in the subject less than 30 minutes after the administration; and thereafter maintaining the mean plasma concentration of the psychedelic at a predetermined value to maintain the dissociative state during a therapeutic window.

Abstract: Provided are improved methods for treating a psychological disorder in a subject comprising administering to the subject an amount of psilocybin or psilocin sufficient to induce a dissociative state in the subject less than 30 minutes after the administration; and thereafter maintaining the mean plasma concentration of the psychedelic at a predetermined value to maintain the dissociative state during a therapeutic window.